Study study type PathologyT1T0Patientssample sizesROB Results deaths (OS) Eprogression or deaths (PFS) ERFS/DFS E

mBC - TNBC - L1 - all population breast cancer - triple negative mBC - Triple negative (TNBC) - 1st Line (L1) mBC - TNBC - L1 - all population

versus Standard of Care (SoC)
veliparib plus paclitaxel plus carboplatin
BrighTNess (velaparib-P-C (arm A) vs paclitaxel - carboplatin (arm B)), 2018
  NCT02032277
RCTmBC - TNBC - L1 - all populationveliparib plus paclitaxel plus carboplatinplacebo plus paclitaxel plus carboplatinPatients: women who had histologically or cytologically confirmed invasive TNBC, clinical stage II-III316 / 160NA
inconclusive
BrighTNess (velaparib-P-C (arm A) vs paclitaxel alone (arm C)), 2018
  NCT02032277
RCTmBC - TNBC - L1 - all populationveliparib plus paclitaxel plus carboplatinplacebo matching veliparib plus placebo matching carboplatin plus paclitaxelPatients: women who had histologically or cytologically confirmed invasive TNBC, clinical stage II-III316 / 158NA
conclusif -18%